Complete financial analysis of Edgewise Therapeutics, Inc. (EWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edgewise Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pilani Investment and Industries Corporation Limited (PILANIINVS.NS) Income Statement Analysis – Financial Results
- PGS ASA (PGEJF) Income Statement Analysis – Financial Results
- Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) Income Statement Analysis – Financial Results
- Ferrovial SE (FER) Income Statement Analysis – Financial Results
- SolarEdge Technologies, Inc. (SEDG) Income Statement Analysis – Financial Results
Edgewise Therapeutics, Inc. (EWTX)
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| Gross Profit | -1.73M | -538.00K | -272.00K | -185.00K | -123.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.91M | 16.61M | 32.19M | 14.98M | 8.62M |
| General & Administrative | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Cost & Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Interest Income | 14.19M | 2.66M | 402.00K | 69.00K | 219.00K |
| Interest Expense | 0.00 | 4.02M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| EBITDA | -112.81M | -67.10M | -42.94M | -17.01M | -9.80M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -114.36M | -22.08M | -43.22M | -17.19M | -9.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.19M | 4.02M | 402.00K | 69.00K | 219.00K |
| Income Before Tax | -100.16M | -19.42M | -42.81M | -17.12M | -9.71M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.02M | -674.00K | -69.00K | -219.00K |
| Net Income | -100.16M | -15.40M | -42.14M | -17.05M | -9.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| EPS Diluted | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Weighted Avg Shares Out | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
| Weighted Avg Shares Out (Dil) | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with...
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects...
Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal
Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive...
7 Small-Cap Stocks to Buy for Large-Scale Gains
Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.
Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will be...
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving...
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment...
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive two-year topline results from the ARCH trial. ARCH is an open label, single-center study assessing safety, tolerability, impact on muscle damage biomarkers, pharmacokinetics (PK)...
Source: https://incomestatements.info
Category: Stock Reports